HK1076812A1 - Cyanoguanidine prodrugs - Google Patents
Cyanoguanidine prodrugsInfo
- Publication number
- HK1076812A1 HK1076812A1 HK05108938.3A HK05108938A HK1076812A1 HK 1076812 A1 HK1076812 A1 HK 1076812A1 HK 05108938 A HK05108938 A HK 05108938A HK 1076812 A1 HK1076812 A1 HK 1076812A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- sub
- prodrugs
- cyanoguanidine
- cyanoguanidine prodrugs
- cancers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38083602P | 2002-05-17 | 2002-05-17 | |
PCT/DK2003/000318 WO2003097601A1 (fr) | 2002-05-17 | 2003-05-15 | Promedicaments de cyanoguanidine |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1076812A1 true HK1076812A1 (en) | 2006-01-27 |
Family
ID=29550021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05108938.3A HK1076812A1 (en) | 2002-05-17 | 2005-10-10 | Cyanoguanidine prodrugs |
Country Status (19)
Country | Link |
---|---|
US (1) | US20070249676A1 (fr) |
EP (1) | EP1507760B1 (fr) |
JP (1) | JP4625694B2 (fr) |
KR (1) | KR101010871B1 (fr) |
CN (1) | CN100503570C (fr) |
AT (1) | ATE368649T1 (fr) |
AU (1) | AU2003229534B2 (fr) |
BR (1) | BR0309996A (fr) |
CA (1) | CA2485351C (fr) |
DE (1) | DE60315288T2 (fr) |
ES (1) | ES2290454T3 (fr) |
HK (1) | HK1076812A1 (fr) |
IL (1) | IL165086A (fr) |
IS (1) | IS7562A (fr) |
MX (1) | MXPA04011322A (fr) |
NO (1) | NO330183B1 (fr) |
PL (1) | PL228742B1 (fr) |
RU (1) | RU2326867C2 (fr) |
WO (1) | WO2003097601A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7253193B2 (en) | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
WO2006066584A1 (fr) | 2004-12-22 | 2006-06-29 | Leo Pharma A/S | Composes de cyanoguanidine |
EP1917244A2 (fr) | 2005-08-24 | 2008-05-07 | Abbott GmbH & Co. KG | Composes guanidine a substitution hetaryl et utilisation en tant que partenaires de liaison pour des recepteurs de 5-ht5 |
US8211912B2 (en) * | 2007-09-26 | 2012-07-03 | Gemin X Pharmaceuticals Canada | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl tranferase inhibitor |
JP5688367B2 (ja) | 2008-08-29 | 2015-03-25 | トポターゲット・アクティーゼルスカブTopoTarget A/S | 新規なウレアおよびチオウレア誘導体 |
WO2010088842A1 (fr) | 2009-02-06 | 2010-08-12 | 天津和美生物技术有限公司 | Compositions pharmaceutiques contenant des pyridyl-cyanoguanidines, leurs méthodes de préparation et utilisations |
JP2012533530A (ja) | 2009-07-17 | 2012-12-27 | トポターゲット・アクティーゼルスカブ | ニコチンアミドホスホリボシルトランスフェラーゼ阻害剤による癌治療の副作用の重症度を低下させるためのニコチン酸またはその前駆体もしくはプロドラッグ投与の有効性を予測するための方法 |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
WO2011121055A1 (fr) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Dérivés de pyridinyle comprenant un groupement cyanoguanidine ou acide squarique |
US9359376B2 (en) * | 2011-04-08 | 2016-06-07 | Sphaera Pharma Pte. Ltd | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds |
BR112014032917A2 (pt) * | 2012-06-27 | 2017-06-27 | Alzheimers Inst Of America Inc | compostos e usos terapêuticos dos mesmos |
CN116640238B (zh) * | 2023-05-30 | 2024-05-03 | 华侨大学 | 一种胍基吡啶壳聚糖鎓盐及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
GB9711125D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
WO2000061559A1 (fr) * | 1999-04-09 | 2000-10-19 | Shionogi Bioresearch Corp. | Composes de cyanoguanidine n-substitues |
AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
US20030045515A1 (en) * | 2001-05-24 | 2003-03-06 | Lise Binderup | Combination medicament for treatment of neoplastic diseases |
CN1662502A (zh) * | 2002-05-17 | 2005-08-31 | 利奥制药有限公司 | 氰基胍前药 |
-
2003
- 2003-05-15 ES ES03722311T patent/ES2290454T3/es not_active Expired - Lifetime
- 2003-05-15 DE DE60315288T patent/DE60315288T2/de not_active Expired - Lifetime
- 2003-05-15 PL PL372769A patent/PL228742B1/pl unknown
- 2003-05-15 CN CNB038140772A patent/CN100503570C/zh not_active Expired - Fee Related
- 2003-05-15 WO PCT/DK2003/000318 patent/WO2003097601A1/fr active IP Right Grant
- 2003-05-15 MX MXPA04011322A patent/MXPA04011322A/es active IP Right Grant
- 2003-05-15 KR KR1020047018603A patent/KR101010871B1/ko active IP Right Grant
- 2003-05-15 AT AT03722311T patent/ATE368649T1/de not_active IP Right Cessation
- 2003-05-15 RU RU2004136991/04A patent/RU2326867C2/ru active
- 2003-05-15 AU AU2003229534A patent/AU2003229534B2/en not_active Ceased
- 2003-05-15 JP JP2004505334A patent/JP4625694B2/ja not_active Expired - Fee Related
- 2003-05-15 BR BR0309996-2A patent/BR0309996A/pt not_active Application Discontinuation
- 2003-05-15 EP EP03722311A patent/EP1507760B1/fr not_active Expired - Lifetime
- 2003-05-15 CA CA2485351A patent/CA2485351C/fr not_active Expired - Lifetime
-
2004
- 2004-11-08 IL IL165086A patent/IL165086A/en active IP Right Grant
- 2004-11-29 IS IS7562A patent/IS7562A/is unknown
- 2004-12-08 NO NO20045374A patent/NO330183B1/no not_active IP Right Cessation
-
2005
- 2005-10-10 HK HK05108938.3A patent/HK1076812A1/xx not_active IP Right Cessation
-
2007
- 2007-06-28 US US11/823,571 patent/US20070249676A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL165086A0 (en) | 2005-12-18 |
WO2003097601A1 (fr) | 2003-11-27 |
ES2290454T3 (es) | 2008-02-16 |
DE60315288D1 (de) | 2007-09-13 |
MXPA04011322A (es) | 2005-02-17 |
IS7562A (is) | 2004-11-29 |
EP1507760B1 (fr) | 2007-08-01 |
NO330183B1 (no) | 2011-02-28 |
BR0309996A (pt) | 2005-02-22 |
RU2004136991A (ru) | 2005-06-10 |
KR20050016412A (ko) | 2005-02-21 |
DE60315288T2 (de) | 2008-04-10 |
US20070249676A1 (en) | 2007-10-25 |
RU2326867C2 (ru) | 2008-06-20 |
IL165086A (en) | 2011-11-30 |
CA2485351A1 (fr) | 2003-11-27 |
ATE368649T1 (de) | 2007-08-15 |
KR101010871B1 (ko) | 2011-01-26 |
PL228742B1 (pl) | 2018-05-30 |
EP1507760A1 (fr) | 2005-02-23 |
NO20045374L (no) | 2004-12-08 |
PL372769A1 (en) | 2005-08-08 |
CN100503570C (zh) | 2009-06-24 |
JP2005538949A (ja) | 2005-12-22 |
AU2003229534B2 (en) | 2009-08-27 |
CA2485351C (fr) | 2011-12-06 |
AU2003229534A1 (en) | 2003-12-02 |
CN1662501A (zh) | 2005-08-31 |
JP4625694B2 (ja) | 2011-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1076812A1 (en) | Cyanoguanidine prodrugs | |
BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
DE60112974D1 (en) | Carbolinderivate | |
GEP20053692B (en) | Substituted Alkylamine Derivatives and Methods of Use | |
IL149402A0 (en) | Arylamine derivatives and their use as anti-telomerase agent | |
MY135477A (en) | 2-(2,6-dichlorophenyl)-diarylimidazoles | |
BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
SG145695A1 (en) | Pyridyl derivatives and their use as therapeutic agents | |
HK1059562A1 (en) | Novel trisubstituted-8h-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of csbp/p38 kinase mediated diseases | |
TW200612910A (en) | Medicaments comprising carbonyl compounds, and the use thereof | |
IL173032A0 (en) | Pyridazine derivatives and their use as therapeutic agents | |
BG108181A (en) | Novel spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
EP1399414A4 (fr) | Composes de tetracycline substitues destines au traitement de la malaria | |
DE60216233D1 (en) | Carbolinderivate | |
EP1572118A4 (fr) | Methodes et compositions de traitement de cancer au moyen des genes 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883 | |
WO2002070469A3 (fr) | Inhibiteurs selectifs de pde3b et leurs utilisations therapeutiques | |
HK1056175A1 (en) | Prodrugs of imidazopyridine derivatives | |
SE0203070D0 (en) | Novel compounds | |
IL157540A0 (en) | N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof | |
GB0018951D0 (en) | Novel compounds | |
EP1551388A4 (fr) | Composes utiles dans le traitement du cancer, compositions et procedes correspondants | |
NO20045373L (no) | Cyanoguanidinprodroger | |
MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
GB0103240D0 (en) | Organic compounds | |
MY133682A (en) | Substituted pyrroles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220515 |